Published 12 days ago • loading... • Updated 12 days ago

Creative Biolabs Advances AI-Driven DMTA Workflow for Drug Discovery and ADMET Optimization

Creative Biolabs integrated AI into its DMTA workflow to accelerate drug discovery by connecting molecular design, synthesis feasibility, and biological testing capabilities.
Traditional DMTA evaluation creates bottlenecks in candidate prioritization; machine learning models trained on DMTA properties now help researchers identify high-potential compounds more efficiently.
The integrated system balances activity, selectivity, and DMTA properties through multi-parameter optimization, delivering ranked candidates with improved ADMET profiles and detailed liability assessments.
Creative Biolabs' multidisciplinary team combines biological expertise with AI technology to accelerate pipelines, enabling proactive candidate design during translational research phases.
Predictive capabilities identify candidates with reduced risk of drug-induced liver injury and Ames mutagenicity early in development, positioning the platform to bridge AI prediction and wet-lab validation.

Insights by Ground AI